يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"ezabenlimab"', وقت الاستعلام: 0.34s تنقيح النتائج
  1. 1
    Academic Journal
    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

    المؤلفون: Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, Geng J, Li J, Teufel M, Märten A, LoRusso P

    المصدر: OncoTargets and Therapy, Vol Volume 17, Pp 267-280 (2024)

    مصطلحات موضوعية: biliary tract cancer • mdm2–p53 antagonist • brigimadlin • ezabenlimab • mdm2-amplified, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    Relation: https://www.dovepress.com/efficacy-and-safety-of-the-mdm2p53-antagonist-brigimadlin-bi-907828-in-peer-reviewed-fulltext-article-OTT; https://doaj.org/toc/1178-6930; https://doaj.org/article/95442fd5c5ce42c0be632413044909c0

    الاتاحة: https://doaj.org/article/95442fd5c5ce42c0be632413044909c0

    View record in BASE Full Text Finder

    أضف إلى المفضلة
  2. 2
    Academic Journal
    Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

    المؤلفون: Markus Zettl, Melanie Wurm, Otmar Schaaf, Sven Mostböck, Iñigo Tirapu, Ilse Apfler, Ivo C. Lorenz, Lee Frego, Cynthia Kenny, Michael Thibodeau, Elisa Oquendo Cifuentes, Markus Reschke, Jürgen Moll, Norbert Kraut, Anne Vogt, Jonathon D. Sedgwick, Irene C. Waizenegger

    المصدر: OncoImmunology, Vol 11, Iss 1 (2022)

    مصطلحات موضوعية: PD-1, LAG-3, ezabenlimab, BI 754091, BI 754111, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/2162-402X

    URL الوصول: https://doaj.org/article/84794c7453c64c359a1ba6066ae5ae77

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  3. 3
    Academic Journal
    Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

    المؤلفون: Stefano Kim, Jihane Boustani, Dewi Vernerey, Véronique Vendrely, Ludovic Evesque, Eric Francois, Laurent Quero, Francois Ghiringhelli, Christelle de la Fouchardière, Laëtitia Dahan, Oliver Bouché, Benoist Chibaudel, Farid El Hajbi, Chloé Vernet, Magali Rebucci-Peixoto, Alexandra Feuersinger, Christophe Maritaz, Christophe Borg

    المصدر: Frontiers in Oncology, Vol 12 (2022)

    مصطلحات موضوعية: ezabenlimab, squamous, anal carcinoma, modified Docetaxel, Cisplatin, 5-Fluorouracil (DCF), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.918499/full; https://doaj.org/toc/2234-943X

    URL الوصول: https://doaj.org/article/08ac6218fcf8493fbfa42d7f8be1d2e4

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء